Monopar Therapeutics Inc.

 

1000 Skokie Blvd., Suite 350

 

Wilmette, Illinois 60091

 

December 29, 2022

 

VIA EDGAR

 

US Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

 

 

Re:  Monopar Therapeutics Inc.

Registration Statement on Form S-3

File No. 333-268935

 

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Monopar Therapeutics Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement be declared effective at 9:00 a.m., Eastern time, on January 4, 2023 or as soon thereafter as practicable, or such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance.

 

Please contact John Harrington of Baker & Hostetler LLP at (216) 861-6697 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement.

 

 

 

Very truly yours,

 

Monopar Therapeutics Inc.

 

 

By: /s/ Chandler D. Robinson

Chandler D. Robinson

Chief Executive Officer